Brain

Article	Citations
Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19	276
COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital	266
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease	249
Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome	222
Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state	221
How patients with multiple sclerosis acquire disability	200
Sleep deprivation impairs molecular clearance from the human brain	182
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease	165
CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease	163
Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons	151
Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI	143
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum	143
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options	142
Neurovascular injury with complement activation and inflammation in COVID-19	141
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease	140
Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis	131
Emerging roles for dynamic aquaporin-4 subcellular relocalization in CNS water homeostasis	127
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease	125
The potential of serum neurofilament as biomarker for multiple sclerosis	124
To what degree is late life cognitive decline driven by age-related neuropathologies?	120
Detection of neuron-derived pathological α-synuclein in blood	117
An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas	117
Acute and non-resolving inflammation associate with oxidative injury after human spinal cord injury	115
Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease	113
Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics	106

Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management	106
Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis	106
The synapse in traumatic brain injury	106
Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability	105
Hearing and dementia: from ears to brain	105
Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder	105
18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases	104
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory	103
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease	99
Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial	97
The Developing Human Connectome Project: typical and disrupted perinatal functional connectivity	97
Multimodal neuroimaging in post-COVID syndrome and correlation with cognition	96
Depression, dementia and immune dysregulation	96
Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants	95
The GGC repeat expansion inNOTCH2NLCis associated with oculopharyngodistal myopathy type 3	93
Developmental and epileptic encephalopathies: what we do and do not know	91
Consciousness among delta waves: a paradox?	90
The role of noradrenaline in cognition and cognitive disorders	90
The microglial component of amyotrophic lateral sclerosis	89
Studying human nociceptors: from fundamentals to clinic	89
Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis	89
The development and convergence of co-pathologies in Alzheimer’s disease	89
Models of psychedelic drug action: modulation of cortical-subcortical circuits	88
Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy	88
Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies	87
Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration	87
The extracellular matrix as modifier of neuroinflammation and remyelination in multiple sclerosis	86
COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis	86
Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications	83
The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease	82
Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence	82
Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial	80
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects	80
Macrophage phagocytosis after spinal cord injury: when friends become foes	79
Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease	78
Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats	78
Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer’s disease	77
Towards network-guided neuromodulation for epilepsy	77
Local sleep-like cortical reactivity in the awake brain after focal injury	77
COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations	76
Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder	76
A new science of emotion: implications for functional neurological disorder	75
Microglial activation and blood–brain barrier permeability in cerebral small vessel disease	74
RFC1 expansions are a common cause of idiopathic sensory neuropathy	74
Anti-amyloid antibody therapies in Alzheimer’s disease	73
A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene	73
Damage to Broca’s area does not contribute to long-term speech production outcome after stroke	72
Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms	72
Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging	72
Reimagining cholinergic therapy for Alzheimer’s disease	71

Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease	71
APOE4 derived from astrocytes leads to blood–brain barrier impairment	70
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects	70
RNA profiling of human dorsal root ganglia reveals sex differences in mechanisms promoting neuropathic pain	70
Modulation of beta bursts in subthalamic sensorimotor circuits predicts improvement in bradykinesia	70
Detecting axonal injury in individual patients after traumatic brain injury	69
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study	69
Evolution of neuroinflammation across the lifespan of individuals with Down syndrome	69
The amyloid cascade hypothesis: an updated critical review	67
Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease	66
KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation	65
Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2	64
Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease	63
Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson’s disease	63
GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition	63
Post-stroke outcomes predicted from multivariate lesion-behaviour and lesion network mapping	63
The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications	62
Genetic, cellular, and connectomic characterization of the brain regions commonly plagued by glioma	62
Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease	62
Driving motor cortex oscillations modulates bradykinesia in Parkinson’s disease	62
A daily temperature rhythm in the human brain predicts survival after brain injury	62
Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit	62
Transcranial alternating current stimulation for treating depression: a randomized controlled trial	61
Diffuse axonal injury has a characteristic multidimensional MRI signature in the human brain	61
SomaticMAP3K3andPIK3CAmutations in sporadic cerebral and spinal cord cavernous malformations	60
Sequence of clinical and neurodegeneration events in Parkinson’s disease progression	60
Stop that! It’s not Tourette’s but a new type of mass sociogenic illness	60
Beyond the average patient: how neuroimaging models can address heterogeneity in dementia	60
COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database	59
Cross-frequency coupling between gamma oscillations and deep brain stimulation frequency in Parkinson’s disease	59
Persistent white matter changes in recovered COVID-19 patients at the 1-year follow-up	59
Microbiota from Alzheimer’s patients induce deficits in cognition and hippocampal neurogenesis	58
Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer’s disease	58
Opening of ATP sensitive potassium channels causes migraine attacks with aura	58
Functional maps of direct electrical stimulation-induced speech arrest and anomia: a multicentre retrospective study	58
Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson’s disease	56
Spreading depolarizations in ischaemia after subarachnoid haemorrhage, a diagnostic phase III study	56
Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia	56
Assessing the landscape of STXBP1-related disorders in 534 individuals	56
Towards realizing the vision of precision medicine: AI based prediction of clinical drug response	56
O-GlcNAcylation regulates dopamine neuron function, survival and degeneration in Parkinson disease	56
Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3	56
Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease	56
From biomechanics to pathology: predicting axonal injury from patterns of strain after traumatic brain injury	55
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics	55
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages	55
Post-acute blood biomarkers and disease progression in traumatic brain injury	55
Recovery from aphasia in the first year after stroke	55
The multifaceted role of neurofilament light chain protein in non-primary neurological diseases	55
Protein contributions to brain atrophy acceleration in Alzheimer’s disease and primary age-related tauopathy	54
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases	54
Gene variant effects across sodium channelopathies predict function and guide precision therapy	54
rs34331204 regulates TSPAN13 expression and contributes to Alzheimer’s disease with sex differences	53
Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators	53
Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy	53
Intrinsic blood–brain barrier dysfunction contributes to multiple sclerosis pathogenesis	52
The neuroethics of disorders of consciousness: a brief history of evolving ideas	52
Cortical disinhibition in Parkinson’s disease	52
Closed-loop stimulation of the medial septum terminates epileptic seizures	52
Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition	52
Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease	52
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis	52
Astrocyte–neuron interplay is critical for Alzheimer's disease pathogenesis and is rescued by TRPA1 channel blockade	52
Comparative connectivity correlates of dystonic and essential tremor deep brain stimulation	51
Impaired dopamine release in Parkinson’s disease	51
Tau accelerates α-synuclein aggregation and spreading in Parkinson’s disease	51
Three-dimensional analysis of synaptic organization in the hippocampal CA1 field in Alzheimer’s disease	51
Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease	50
Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice	49
KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum	49
Neurovascular coupling mechanisms in health and neurovascular uncoupling in Alzheimer’s disease	49
Surface-in pathology in multiple sclerosis: a new view on pathogenesis?	49
Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition	49
ATP1A2- and ATP1A3-associated early profound epileptic encephalopathy and polymicrogyria	49
A brain network for deep brain stimulation induced cognitive decline in Parkinson’s disease	48
Severe COVID-19-related encephalitis can respond to immunotherapy	48
The functional role of the precuneus	48
Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses	47
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment	47
Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe	47

Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma	47
Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma	47
The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?	47
Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders	47
Therapeutic reversal of Huntington’s disease by in vivo self-assembled siRNAs	47
The structural connectome and motor recovery after stroke: predicting natural recovery	47
5′ UTR CGG repeat expansion inGIPC1is associated with oculopharyngodistal myopathy	47
Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis	46
BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain	46
Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study	46
Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes	46
Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement	46
Cardiovascular brain impulses in Alzheimer’s disease	45
Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia	44
Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7	44
Neurological manifestations of COVID-19 in adults and children	44
Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study	44
UNC13B variants associated with partial epilepsy with favourable outcome	44
The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial	44
Proposed research criteria for prodromal behavioural variant frontotemporal dementia	44
Spatiotemporal features of β-γ phase-amplitude coupling in Parkinson’s disease derived from scalp EEG	43
VEGF signalling causes stalls in brain capillaries and reduces cerebral blood flow in Alzheimer’s mice	43
DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy	43
Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease	42
Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy	42
GPR151 in nociceptors modulates neuropathic pain via regulating P2X3 function and microglial activation	42
Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer’s disease	42
Interpretable surface-based detection of focal cortical dysplasias: a Multi-centre Epilepsy Lesion Detection study	42
A review of Mendelian randomization in amyotrophic lateral sclerosis	42
Vestibular agnosia in traumatic brain injury and its link to imbalance	42
Subthalamic stimulation impairs stopping of ongoing movements	42
The radiologically isolated syndrome: revised diagnostic criteria	41
Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension	41
Neuronal intranuclear inclusion disease in patients with adult-onset non-vascular leukoencephalopathy	41
A Mendelian randomization study investigating the causal role of inflammation on Parkinson’s disease	41
Source-sink connectivity: a novel interictal EEG marker for seizure localization	41
A neural network for tics: insights from causal brain lesions and deep brain stimulation	40
Somatic variants in diverse genes leads to a spectrum of focal cortical malformations	40
Susac syndrome: challenges in the diagnosis and treatment	40
Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention	40
Normative intracranial EEG maps epileptogenic tissues in focal epilepsy	40
Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer’s disease	40
All or nothing belief updating in patients with schizophrenia reduces precision and flexibility of beliefs	40
Predicting amyloid PET and tau PET stages with plasma biomarkers	40
Common molecular mechanisms ofSLC6A1variant-mediated neurodevelopmental disorders in astrocytes and neurons	40
Dissecting autism and schizophrenia through neuroimaging genomics	39
In-depth analysis reveals complex molecular aetiology in a cohort of idiopathic cerebral palsy	39
Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson’s disease	39
Engineered microRNA-based regulatory element permits safe high-dose miniMECP2gene therapy in Rett mice	39
GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response	39
Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation	39
Educational attainment, structural brain reserve and Alzheimer’s disease: a Mendelian randomization analysis	39
Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns	38
Heterozygous PRKN mutations are common but do not increase the risk of Parkinson’s disease	38
Motor neuron pathology in CANVAS due to RFC1 expansions	38
Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy	38
Motor cortex stimulation for chronic neuropathic pain: results of a double-blind randomized study	38
Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study	38
The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial	38
Spatiotemporal dynamics between interictal epileptiform discharges and ripples during associative memory processing	38
De novopurine biosynthesis is a major driver of chemoresistance in glioblastoma	38
Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer’s disease	38
MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response	38
Medial septal GABAergic neurons reduce seizure duration upon optogenetic closed-loop stimulation	37
Pain and depression comorbidity causes asymmetric plasticity in the locus coeruleus neurons	37
A clinical primer for the glymphatic system	37
Dendritic pathology, spine loss and synaptic reorganization in human cortex from epilepsy patients	37
Medullary kappa-opioid receptor neurons inhibit pain and itch through a descending circuit	37
Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer’s disease	37
Normative brain mapping of interictal intracranial EEG to localize epileptogenic tissue	37
Silent cold-sensing neurons contribute to cold allodynia in neuropathic pain	36
Effect of a novel nasal oxytocin spray with enhanced bioavailability on autism: a randomized trial	36
Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations	36
Resting-state EEG reveals four subphenotypes of amyotrophic lateral sclerosis	36
Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord	36
Astrocyte immunometabolic regulation of the tumour microenvironment drives glioblastoma pathogenicity	35
Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder	35
Huntington’s disease-specific mis-splicing unveils key effector genes and altered splicing factors	35
Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study	35
Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia	35
Uncovering the prevalence and neural substrates of anhedonia in frontotemporal dementia	35
Sex differences in the genetic architecture of cognitive resilience to Alzheimer’s disease	35
Bi-allelic variants in HOPS complex subunit VPS41 cause cerebellar ataxia and abnormal membrane trafficking	35
Interictal spikes with and without high-frequency oscillation have different single-neuron correlates	35
Cerebrovascular insulin receptors are defective in Alzheimer’s disease	35
Multimodal prediction of residual consciousness in the intensive care unit: the CONNECT-ME study	35
Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms	34
Dissecting the shared genetic basis of migraine and mental disorders using novel statistical tools	34
Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study	34
Balance between competing spectral states in subthalamic nucleus is linked to motor impairment in Parkinson’s disease	34
Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study	34
A brain atlas of axonal and synaptic delays based on modelling of cortico-cortical evoked potentials	34
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity	34
Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease	34
Clinical and genetic spectra of 1550 index patients with hereditary spastic paraplegia	34